Projected to grow from US$23.13 billion in 2024 to US$37.07 billion by 2033 at 5.4% CAGR, the next-gen MM therapies market thrives on drug classes and transplant post-maintenance. Dive into segmentation by therapy type, NCCN guidelines, and challenges in genetic risk stratification. https://finance.yahoo.com/news/next-generation-multiple-myeloma-therapies-112000005.html